A 3-gene PI stratifies survival in adult AML patients with different ELN cytogenetic risk (discovery series). (A) AUC curves quantify the ability of our 3-gene PI to predict outcome in individual patients (specificity and sensitivity) within the first 48 months of treatment initiation. AUC = 1.0 would denote perfect prediction, and AUC = 0.5 would denote no predictive ability. (B) Kaplan-Meier estimates of EFS and OS in AML patient subgroups (discovery series) with specific ELN cytogenetic risk. Survival curves were compared using a log-rank (Mantel-Cox) test.